Wednesday 6-25-2014 Bristol-Myers Squibb Company (BMY) $BMY opened at 49.27 hitting the high price of 49.99 and a day low of 49.11 with a total volume of 16,412,161. BMY had a previous close of 48.30 and has been seeing an average volume of 10,216,600.
Overall Average: 8% Buy
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - 1 hr 41 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 2.96%
Comtex SmarTrend(R) - Wed Jun 25, 3:43PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.11 to a high of $49.99. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $48.44 on volume of 16.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
After Yesterday's Rally of 2.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 25, 3:42PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.11 to a high of $49.99. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $48.44 on volume of 16.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Most active New York Stock Exchange-traded stocks
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)
Midday Glance: Pharmaceuticals companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.: (full story)
Humana Hires Experienced Business/Government Executive To Lead Company's Washington D.C.-based Federal Affairs
Business Wire - Wed Jun 25, 12:00PM CDT
Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, has hired Douglas M. Stoss to fill the role of Vice President of Federal Affairs. Stoss will be responsible for leading Humana's federal advocacy and engagement efforts, based in the company's Washington D.C. office. He brings substantial public and private sector experience to the Fortune 100 health care company. (full story)
3 Huge Stocks to Trade (or Not)
at The Street - Wed Jun 25, 11:59AM CDT
Here's how to trade some of the most active stocks on the market today. (full story)
Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today
at The Street - Wed Jun 25, 11:21AM CDT
Bristol-Meyers Squibb (BMY) is rising after it announced positive results in the clinical trials of its melanoma treatment. (full story)
Bristol-Myers Stock Up On Nivolumab Trial Success
at Investor's Business Daily - Wed Jun 25, 10:11AM CDT
Bristol-Myers Squibb (BMY) stock was up nearly 3% in early trading on the stock market today, after late Tuesday's news that the big pharma had stopped a trial of its cancer drug nivolumab early due to strong efficacy. The trial in question compared... (full story)
Bristol-Myers Squibb partners with Academic Research Institute to expand access to clinical trial data
M2 - Wed Jun 25, 4:57AM CDT
Biopharmaceutical company Bristol-Myers Squibb (NYSE:BMY) revealed on Tuesday that it has signed a clinical trial transparency agreement with Duke University's Duke Clinical Research Institute (DCRI), an academic clinical research organisation that conducts groundbreaking multinational clinical trials. (full story)
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off. (full story)
BRISTOL-MYERS SQUIBB
at Investor's Business Daily - Tue Jun 24, 5:51PM CDT
BRISTOL-MYERS SQUIBB (BMY) said a late-stage trial of its cancer drug nivolumab on advanced melanoma patients was halted early after it was determined the drug was likely to prolong survival. Analysts have forecast potential multibillion-dollar sales... (full story)
Bristol-Myers says cancer drug met goal in study
AP - Tue Jun 24, 5:32PM CDT
NEW YORK (AP) — Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. (full story)
Pharma’s Huge Bet on Immunotherapies
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Large pharmaceutical companies are pouring billions worth of funding into a new generation of anti-cancer drugs that use a newly discovered biological mechanism to trigger a strong immune response against tumors. This mechanism is centered around the... (full story)
Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
Business Wire - Tue Jun 24, 3:45PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent Data Monitoring Committee (DMC) showed evidence of superior overall survival in patients receiving nivolumab compared to the control arm. Patients in the trial will be unblinded and allowed to cross over to nivolumab. The Company will share these data with health authorities. (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Will This Price Target Decrease Hurt Bristol-Myers Squibb (BMY) Stock Today?
at The Street - Tue Jun 24, 8:07AM CDT
Jefferies lowers its price target for Bristol-Myers Squibb (BMY) to $42 from $47, reiterating its 'hold' rating. (full story)
Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
Business Wire - Tue Jun 24, 7:01AM CDT
Bristol-Myers Squibb (NYSE:BMY) today announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency. Bristol-Myers Squibb will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements. The collaboration with DCRI is one of a series of initiatives by Bristol-Myers Squibb to support data sharing and enhance the company's existing policies on transparency and disclosure of clinical trial information. Clinical trial information being made available for scientific research will include protocols, full clinical study reports (CSR) and de-identified patient-level data and study-level data for medicines and indications approved in the U.S. and/or Europe for trials completed after January 2008. Information from terminated programs will be available two years after discontinuation. (full story)
Overall Average: 8% Buy
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - 1 hr 41 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Bristol-Myers Squibb Set to Possibly Pullback After Yesterday's Rally of 2.96%
Comtex SmarTrend(R) - Wed Jun 25, 3:43PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.11 to a high of $49.99. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $48.44 on volume of 16.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
After Yesterday's Rally of 2.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 25, 3:42PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.11 to a high of $49.99. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $48.44 on volume of 16.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Most active New York Stock Exchange-traded stocks
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)
Midday Glance: Pharmaceuticals companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.: (full story)
Humana Hires Experienced Business/Government Executive To Lead Company's Washington D.C.-based Federal Affairs
Business Wire - Wed Jun 25, 12:00PM CDT
Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, has hired Douglas M. Stoss to fill the role of Vice President of Federal Affairs. Stoss will be responsible for leading Humana's federal advocacy and engagement efforts, based in the company's Washington D.C. office. He brings substantial public and private sector experience to the Fortune 100 health care company. (full story)
3 Huge Stocks to Trade (or Not)
at The Street - Wed Jun 25, 11:59AM CDT
Here's how to trade some of the most active stocks on the market today. (full story)
Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today
at The Street - Wed Jun 25, 11:21AM CDT
Bristol-Meyers Squibb (BMY) is rising after it announced positive results in the clinical trials of its melanoma treatment. (full story)
Bristol-Myers Stock Up On Nivolumab Trial Success
at Investor's Business Daily - Wed Jun 25, 10:11AM CDT
Bristol-Myers Squibb (BMY) stock was up nearly 3% in early trading on the stock market today, after late Tuesday's news that the big pharma had stopped a trial of its cancer drug nivolumab early due to strong efficacy. The trial in question compared... (full story)
Bristol-Myers Squibb partners with Academic Research Institute to expand access to clinical trial data
M2 - Wed Jun 25, 4:57AM CDT
Biopharmaceutical company Bristol-Myers Squibb (NYSE:BMY) revealed on Tuesday that it has signed a clinical trial transparency agreement with Duke University's Duke Clinical Research Institute (DCRI), an academic clinical research organisation that conducts groundbreaking multinational clinical trials. (full story)
'Fast Money' Recap: A Mixed Bag for Housing
at The Street - Wed Jun 25, 4:00AM CDT
The trading panel discussed the stock market's big drop, how low the S&P can go and why bonds aren't selling off. (full story)
BRISTOL-MYERS SQUIBB
at Investor's Business Daily - Tue Jun 24, 5:51PM CDT
BRISTOL-MYERS SQUIBB (BMY) said a late-stage trial of its cancer drug nivolumab on advanced melanoma patients was halted early after it was determined the drug was likely to prolong survival. Analysts have forecast potential multibillion-dollar sales... (full story)
Bristol-Myers says cancer drug met goal in study
AP - Tue Jun 24, 5:32PM CDT
NEW YORK (AP) — Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. (full story)
Pharma’s Huge Bet on Immunotherapies
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Large pharmaceutical companies are pouring billions worth of funding into a new generation of anti-cancer drugs that use a newly discovered biological mechanism to trigger a strong immune response against tumors. This mechanism is centered around the... (full story)
Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
Business Wire - Tue Jun 24, 3:45PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent Data Monitoring Committee (DMC) showed evidence of superior overall survival in patients receiving nivolumab compared to the control arm. Patients in the trial will be unblinded and allowed to cross over to nivolumab. The Company will share these data with health authorities. (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Will This Price Target Decrease Hurt Bristol-Myers Squibb (BMY) Stock Today?
at The Street - Tue Jun 24, 8:07AM CDT
Jefferies lowers its price target for Bristol-Myers Squibb (BMY) to $42 from $47, reiterating its 'hold' rating. (full story)
Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
Business Wire - Tue Jun 24, 7:01AM CDT
Bristol-Myers Squibb (NYSE:BMY) today announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency. Bristol-Myers Squibb will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements. The collaboration with DCRI is one of a series of initiatives by Bristol-Myers Squibb to support data sharing and enhance the company's existing policies on transparency and disclosure of clinical trial information. Clinical trial information being made available for scientific research will include protocols, full clinical study reports (CSR) and de-identified patient-level data and study-level data for medicines and indications approved in the U.S. and/or Europe for trials completed after January 2008. Information from terminated programs will be available two years after discontinuation. (full story)
